Table 2.
Alternative Nanoparticles Studied in Animal Models of Stroke, Categorized According to Carrier Material Composition and Functionalization
| Carrier: Property | Functional Component | Therapeutic Agent | Animal: Disease Model (Route) | Source |
|---|---|---|---|---|
| MICELLES: Controlled degradability, coated, conjugated, mixed, loaded | Degradable motif, phospholipid coat, cell membrane coat, chitosan coat, tween80, polysorbate 80, amino-TEMPO, AMD3100, A2AR agonist, ApoE, anti-NR1, BHEM-Chol, CBSA, chlorotoxin, CREKA, HSAP, dexamethasone, lexiscan, WGA | catalase, curcumin, dexamethasone, edaravone, glyburide, glycyrrhizic acid, PNS, HSAP, luteolin, NGF, MRZ2/576, NEP1-40, NR2B9C, puerarin, rapamycin, amino-TEMPO, resveratrol, riluzole, superoxide dismutase, tanshinone IIA, C3 siRNA, HO-1 plasmid, miR-195 | Mouse: tMCAO (IA, IV), thrombotic stroke (IV) Rat: tMCAO (IA, IC, IN, IP, IV, IG), pMCAO (IV), thrombotic stroke (IA), hemorrhagic stroke (IV), global transient ischemia (IG) |
62–90 |
| DENDRIMERS: Controlled degradability, conjugated, loaded, tectonic | Degradable motif, dexamethasone, PGP | Catalase, HMGB-1 siRNA, HO-1 plasmid, dexamethasone | Mouse: tMCAO (IV), pMCAO (IV), unilateral cortical devascularization (IC) Rat: tMCAO (IC, IN, IV) |
92–97 |
| NANOGELS: Controlled release, loaded | Glycol chitosan, PEG-UK | UK, uPA | Rat: pMCAO (IV) | 99,100 |
| INORGANIC NANOPARTICLES: Conjugated, coated, loaded | LXW7, PEG-ANG coat, phospholipid coat, silica coat | CeO2, Pt, EPCs, edaravone, tPA | Mouse: tMCAO (IV), thrombotic stroke (IA) Rat: tMCAO (IV), hemorrhagic stroke (IV) |
101–107 |
| CARBON ALLOTROPES: Conjugated, coated, modified | Glucosamine, hydrocarbon layer, amine group, carboxyl group, polyhydroxyl group, sulfobutyl group | Carboxyfullerene, FC4S, fullerenol, glucosamine, C3 siRNA, NPCs | Rat: tMCAO (IC, IP, IV), ET-1 stroke (IC) | 108–112,114,115,117 |